|
SATURDAY, MARCH 19, 2016 |
HALL B |
|
| 08:30-10:20 |
TREATMENT AND PROGNOSIS OF EPILEPSY |
|
Chairs: Nuno Canas, Portugal; Thanos Covanis, Greece |
| 08:30-09:25 |
Proposition: Carbamazepine (CBZ) is an outmoded drug and should never be used as a first-line therapy |
|
Capsule: CBZ is an effective antiepileptic drug, advocated by the ILAE as a first-line agent. However, studies in recent years have elucidated new risks and problems associated with its prescription. Should it remain listed as a first-line agent, or should it be relegated to secondary or tertiary use once other agents have failed? |
| 08:30-08:40 |
Host: João Chaves, Portugal |
| 08:40-08:55 |
Pro: Martin Brodie, UK |
| 08:55-09:10 |
Con: Cigdem Ozkara, Turkey |
| 09:10-09:25 |
Discussion and rebuttals |
|
| 09:25-10:20 |
Can we predict with reasonable confidence which patients with idiopathic generalized epilepsy (IGE) will remit? |
|
Capsule: These are often considered benign and liekly to remit. Is this true? Do some patients require lifetime treatment and can one predict who they are? This will require a review of the different syndromes and discussion of prognosis |
| 09:25-09:35 |
Host: Alla Guekht, Russia |
| 09:35-09:50 |
Yes: Elinor Ben Menachem, Sweden |
| 09:50-10:05 |
No: Martin Holtkamp, Germany |
| 10:05-10:20 |
Discussion and rebuttals |
|
| 10:35-12:25 |
Session 22 | DIAGNOSTIC EVALUATION |
|
Chairs: Nandan Yardi, India; Francisco Sales, Portugal |
| 10:35-11:30 |
Should we regularly check for autoimmune causes in patients with refractory epilepsy without other obvious causes? |
|
Capsule: Autoimmune disorders are increasingly being recognized; how often should we check for these? This will require discussion of the different types of autoimmune epilepsies, epidemiology, diagnostic criteria, treatment and economic considerations |
| 10:35-10:45 |
Host: Ilan Blatt, Israel |
| 10:45-11:00 |
Yes: Alla Guekht, Russia |
| 11:00-11:15 |
No: William Theodore, USA |
| 11:15-11:30 |
Discussion and rebuttals |
|
| 11:30-12:25 |
Can the Wada test be replaced by fMRI and other techniques? |
|
Capsule: The Wada test has been used for decades to lateralize the language dominant hemisphere and assess memory in advance of epilepsy surgery, particularly for mesial temporal resections. However, it poses risk and causes discomfort, and its value in predicting postoperative amnesia has not been validated. fMRI tasks have been developed to localize and lateralize language and memory. Can this non-invasive test replace the Wada test? |
| 11:30-11:40 |
Host: Isabel Santana, Portugal |
| 11:40-11:55 |
Yes: Michael Sperling, USA |
| 11:55-12:10 |
No: Cigdem Ozkara, Turkey |
| 12:10-12:25 |
Discussion and rebuttals |
|
| 15:00-17:00 |
Session 23 | EPILEPSY TREATMENT I |
|
Chairs: Makarand Bagul, UK; Jose Lopes Lima, Portugal |
| 15:00-16:00 |
Should combination therapy be used after failure of monotherapy with one or two antiepileptic drugs? |
|
Capsule: How many drugs should be tried in monotherapy before resorting to combination therapy, given the variety of mechanisms to try with different therapeutic agents? |
| 15:00-15:10 |
Host: Manjari Tripathi, India |
| 15:10-15:25 |
Yes: Martin Brodie, UK |
| 15:25-15:40 |
No: Elinor Ben Menachem, Sweden |
| 15:40-16:00 |
Discussion and rebuttals |
|
| 16:00-17:00 |
Should responsive neurostimulation be offered in preference to other forms of neurostimulation when a well defined focus is known? |
|
Capsule: A variety of neurostimulation techniques are now available, including, responsive neurostimulation, vagus nerve stimulation, and trigeminal nerve stimulation. Responsive neurostimulation is the only technique that provides stimulation directly at the location of the presumed epileptic focus. Is this method superior? |
| 16:00-16:10 |
Host: Michael Sperling, USA |
| 16:10-16:25 |
Yes: Michael Sperling, USA |
| 16:25-16:40 |
No: Martin Holtkamp, Germany |
| 16:40-17:00 |
Discussion and rebuttals |
|
| 17:15-19:00 |
Session 24 | EPILEPSY TREATMENT II |
|
Chair: Konrad Rejdak, Poland |
| 17:15-18:10 |
Debate: Should non-convulsive status epilepticus be treated aggressively? |
|
Capsule: How harmful is non-convulsive status? Is there really evidence to support aggressive therapy? What about risks of therapy, data regarding prognosis? |
| 17:15-17:25 |
Host: Ivan Rektor, Czech Republic |
| 17:25-17:40 |
Yes: Manjari Tripathi, India |
| 17:40-17:55 |
No: Ilan Blatt, Israel |
| 17:55-18:10 |
Discussion and rebuttal |
|
| 18:10-19:00 |
CASE DISCUSSION |
|
Moderators: Francisco Sales, Portugal & Michael Sperling, USA |
